Revolution Medicines (RVMD) Other financing activities (2019 - 2026)

Revolution Medicines has reported Other financing activities for 8 years, with the latest figure at $28.8 million in Q2 2026.

• On a quarterly basis, Other financing activities rose 1389.11% year-over-year to $28.8 million in Q2 2026; TTM through Jun 2026 was $59.4 million, a 36.24% decrease from a year earlier, with the FY2025 full-year figure at $21.1 million, down 77.85% from the prior year.
• Other financing activities was $28.8 million for Q2 2026 at Revolution Medicines, up from $12.2 million in the prior quarter.
• The five-year high for Other financing activities was $87.3 million in Q4 2024, with the low at $190000.0 in Q2 2022.
• Average Other financing activities over 5 years is $9.0 million, with a median of $1.2 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Other financing activities soared 6422.5% in 2024, then sank 83.77% in 2025.
• Over 5 years, Other financing activities stood at $777000.0 in 2022, then jumped by 72.2% to $1.3 million in 2023, then jumped by 6422.5% to $87.3 million in 2024, then plunged by 83.77% to $14.2 million in 2025, then surged by 103.69% to $28.8 million in 2026.
• The last three Other financing activities figures came in at $28.8 million (Q2 2026), $12.2 million (Q1 2026), and $14.2 million (Q4 2025), per Business Quant data.